Anna D. Garrett, PharmD, BCPS
Anna D. Garrett is a clinical pharmacist and president of Dr. Anna Garrett (www.drannagarrett.com). Her mission is to help women in midlife maximize their mojo! Contact her at [email protected]
Dabigatran as effective as warfarin to prevent VTE recurrence
Data from the RE-MEDY trial suggest that Pradaxa is as effective as warfarin for long-term, extended antithrombotic therapy in patients who have already received at least three months of anticoagulation for VTE
Apixaban added to anticoagulant arsenal
FDA recently approved apixaban for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
Antidote for new anticoagulants studied
A universal antidote for factor Xa inhibitors has entered phase 2 studies.
Rivaroxaban has more indications
Rivaroxaban has more indications
The FDA has increased the indications for rivaroxaban. Patients with stents who receive oral anticoagulants do not need aspirin. Low-dose aspiring has shown some ability to reduce venous thromboembolism.
Merck Moves Forward with Plans for Vorapaxar Approval
Anticoagulation therapies reviewed, including Merck moving forward with FDA approval of vorapaxar despite bleeding risks
Ticagrelor tops prasugrel in pharmacodynamic study
Ticagrelor is shown to be better at platelet inhibition. Warfarin seen as beneficial to patients with PAH. Dabigatran's problems aren't over.
Fondaparinux safe in renal impairment
Fondaparinux shown to be safe for patients with renal impairment.
Panel says no to rivaroxaban for ACS
FDA says no to rivaroxaban for ACS. ACCP updates DVT evidence. Fatal bleeds from dabigatran have tapered off
CHADS2 scoring debate continues
The debate on CHADS2 scoring vs. CHA2DS2-VASc continues
New CAD/ACS antiplatelet agents a mixed bag
New CAD/ACS antiplatelet agents a mixed bag.

Poll